ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,693Medicare Part D Prescriptions Filled, Including Refills

Rank: 170 out of 1206

$460K Total Retail Price of All Prescriptions

Rank: 212 out of 1206

410 Patients Receiving at Least One Drug in Part D
86%Patients 65 Years and Older
20% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Iowa
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 410 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

7% of this provider’s 410 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

2% of this provider’s 9,597 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$43 was the average price of a prescription from this provider, compared to $46 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Iowa
SIMVASTATIN 712 669 1 1
LEVOTHYROXINE SODIUM 562 529 2 2
WARFARIN SODIUM 372 349 3 8
OMEPRAZOLE 365 325 4 3
LISINOPRIL 361 330 5 4
METOPROLOL SUCCINATE 319 293 6 15
MELOXICAM 301 258 7 35
FUROSEMIDE 301 281 7 5
CITALOPRAM HBR 293 287 9 16
METOPROLOL TARTRATE 287 273 10 9
FENOFIBRATE 270 247 11 56
AMLODIPINE BESYLATE 231 208 12 6
METFORMIN HCL 217 205 13 10
HYDROCHLOROTHIAZIDE 158 147 14 11
ATENOLOL 138 138 15 14
ZOLPIDEM TARTRATE 127 118 16 25
GABAPENTIN 113 95 17 18
POTASSIUM CHLORIDE 112 111 18 12
ALENDRONATE SODIUM 107 100 19 19
HYDROCODONE-ACETAMINOPHEN 105 100 S3 20 7
ATORVASTATIN CALCIUM 104 102 21 13
ENALAPRIL MALEATE 97 89 22 45
SERTRALINE HCL 96 81 23 22
DIGOXIN 95 83 24 43
JANTOVEN 94 85 25 95
TRAMADOL HCL 93 82 26 17
TAMSULOSIN HCL 85 85 27 26
ZETIA 85 81 27 73
LOSARTAN POTASSIUM 79 71 29 20
LANTUS 78 71 30 38
NEXIUM 74 62 31 47
LISINOPRIL-HYDROCHLOROTHIAZIDE 73 73 32 27
ISOSORBIDE MONONITRATE ER 73 73 32 40
LEVOFLOXACIN 71 63 34 78
DONEPEZIL HCL 71 71 34 29
CIPROFLOXACIN HCL 67 61 36 61
RANITIDINE HCL 63 59 37 23
DETROL LA 59 59 38 125
ALLOPURINOL 58 58 39 24
BENAZEPRIL HCL 58 58 39 39
LANTUS SOLOSTAR 55 50 41 85
CEFDINIR 53 45 42 161
NAMENDA 53 53 42 36
CRESTOR 50 50 44 30
SYNTHROID 50 50 44 94
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 14, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.